Across TCGA pan-cancer cohorts, EEF1AKMT3 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated EEF1AKMT3 data layer compared with 27 for mass-spec protein.
The strongest signal is observed in stomach adenocarcinoma (STAD), where higher EEF1AKMT3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated EEF1AKMT3 expression acts as an unfavorable survival marker.
STAD and UCEC are the cancer types where EEF1AKMT3 Mutation most reproducibly stratifies survival.